IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Arms / Cohorts
Experimental:Phase 1: IDP-023 (Single Dose)
Accepting patients
Experimental:Phase 1: IDP-023 (Multiple Doses)
Accepting patients
Experimental:Phase 1: IDP-023 + IL-2
Accepting patients
Experimental:Phase 2: IDP-023 + Rituximab
Not yet accepting
Experimental:Phase 2: IDP-023 + Daratumumab
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.